PHILADELPHIA—Approximately 60 research abstracts on gout were accepted for presentation at ACR Convergence 2022, including two plenary abstract presentations. It is exciting to see a wealth of research on gout being undertaken worldwide. Here, we highlight important points from seven of these studies. 1. Abstract 1810: Frequency and Patterns of Opioid Use in the Management…
Despite an expanding armamentarium of disease-modifying treatments for rheumatoid arthritis (RA), some patients with RA remain symptomatic.1 Current treatment guidelines from both the ACR and the European Alliance of Associations for Rheumatology (EULAR) recommend treat-to-target strategies to achieve remission or low disease activity, and patients want to feel better.2,3 So how can we best help…
In a post hoc analysis of two clinical trials, Maassen et al. demonstrated that 40% of patients with early RA or undifferentiated arthritis experienced disease flare after primary glucocorticoid discontinuation despite background treatment with conventional synthetic DMARDs.
Thomas Dörner, MD, reviewed the current state of systemic lupus erythematosus (SLE) management, providing updates on novel therapies and insights into the pathogenesis of SLE.
From the first substantial argument in the 19th century that uric acid played a role in gout, it took about 100 years for the medical community to accept its role in triggering acute inflammatory gout attacks. Two papers, both published in 1962, helped demonstrate the link between uric acid and acute gout attacks, quickly opening…
At this EULAR 2022 session, one expert explains why he believes refractory gout is caused by mismanagement and discussed ways around treatment obstacles.
This EULAR 2022 session discussed the increasing role of imaging in the diagnosis of gout.
New analyses of treat to target in gout may lead to revisions in some guidelines.
Because rheumatologists and mental health experts both treat patients with depression, anxiety, pain, disability and sleep disorders, provider cross-training may benefit patients and providers themselves. “When a patient has active psychosocial distress, this has a negative effect on their physical function. Similarly, if a patient has active physical symptoms, like a rheumatoid arthritis flare, this…
ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric…